Skip to content

Immune and Cognitive Benefits of Mango Intake in Young Adults

Immune and Cognitive Benefits of Mango Intake in Young Adults: A Randomized Trial

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06229262
Enrollment
54
Registered
2024-01-29
Start date
2026-12-01
Completion date
2027-12-01
Last updated
2026-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognition, Immunity

Keywords

Mango, Immunity, cognition

Brief summary

The main objectives of our proposed study are to determine the effects of mango consumption on immune and cognitive functions in free-living college going young adults aged 18-30 years

Detailed description

The main objectives of our proposed study are to determine the effects of mango consumption on immune and cognitive functions in free-living college going young adults aged 18-30. To accomplish these objectives, a randomized controlled, parallel design study is proposed with two groups consuming their habitual diet, but with one (Mango group) receiving 1.5 servings of mango/day and the other (Control group) abstaining from eating any mango for the duration of the study.

Interventions

DIETARY_SUPPLEMENTMango group

Participants will consume 1.5 cups of mangos per day for 12 weeks.

Sponsors

Loma Linda University
Lead SponsorOTHER
National Mango Board
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Investigator, Outcomes Assessor)

Masking description

The investigator and outcome assessor will not be aware of which participant is in which arm

Intervention model description

this will be a12 week, parallel study , free living with college going young adults aged 18-30 years

Eligibility

Sex/Gender
ALL
Age
18 Years to 30 Years
Healthy volunteers
Yes

Inclusion criteria

* Male and female college students aged 18-30 years

Exclusion criteria

* known intolerance or allergy to mangos * regular intake of mangos and/or fruits of a similar nutritional content such as peach, nectarine, papaya, apricot and cantaloupe * using cognition and/or immune-boosting supplements or vitamins * recent exposure to antibiotics and corticoids * uncontrolled chronic diseases and mental illnesses, clinical depression, and immunocompromised state

Design outcomes

Primary

MeasureTime frameDescription
Changes in lymphocyte populationsbaseline to 12 weeksImmunophenotyping will be performed by flow cytometry to measure the number of T helper, T cytotoxic, Naive and memory cells and B cells
Changes in Lymphocyte activitybaseline to 12 weeksThe production of lymphocytes will be measured in the supernatant using enzyme linked immunosorbent assay (ELISA)
Changes in cytokine productionbaseline to 12 weeksThe cytokines produced due to lymphocyte activity will be measured in the supernatant using enzyme linked immunosorbent assay (ELISA)
Changes in serum inflammatory cytokine concentrationbaseline to 12 weekschanges in the concentrations of the inflammatory cytokines will be performed on serum using enzyme linked immunoassay (ELISA) will include hs-CRP, interleukin (IL)-1B, IL-6, TNF a, IL-10, IL-2, IFN-γ, E-selectin,
changes from baseline in global cognitive composite scorebaseline to 12 weeksThe composite score will be calculated using the scores from the tests listed below. Scores will be calculated with the standardized scores of each test as the score of each participant minus the group mean and divide by its standard deviation. The composite score is the mean of the standardized scores. the 5 tests are: Rey Auditory Verbal Learning Test (RAVLT), Brief Visuospatial Memory Test, Digit Span, FAS Word Fluency, Symbol Digit Modalities Test
Change in serum brain-derived neurotrophic factor (pg/mL)baseline to 12 weekschanges in serum brain-derived neurotrophic factor (pg/mL) assessed by ELISA

Countries

United States

Contacts

CONTACTSujatha Rajaram, PhD
srajaram@llu.edu909-558-4300
CONTACTAmandeep Wright, MPH
amawright@llu.edu909-558-4300
PRINCIPAL_INVESTIGATORSujatha Rajaram, PhD

Loma Linda University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 11, 2026